This Week in Rheumatology — Jul 2, 2026

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning predicting and preventing disease progression in psoriatic arthritis, cardiorenal management in systemic autoimmune diseases, and novel clinical tools for patient phenotyping and care delivery. Let's dive in.

We begin in the field of psoriatic arthritis, where two new studies published in Rheumatology (Oxford) shed light on how we can predict and prevent disease progression. First, the FOREMOST trial evaluated the transition from early, oligoarticular psoriatic arthritis to polyarticular disease, and whether early intervention can modify this course [1]. This randomized controlled trial enrolled three hundred and eight patients with early disease—averaging about ten months of symptoms—and limited joint involvement, defined as having between one and four swollen and tender joints. Patients were randomized to receive either apremilast or placebo for twenty-four weeks, followed by open-label apremilast through week forty-eight. At baseline, eighty-seven percent of the cohort had true oligoarticular disease. Strikingly, a quarter of the patients in the placebo group progressed to polyarticular disease by week sixteen. However, early initiation of apremilast reduced the odds of this progression by fifty-eight percent. When looking closely at the placebo group, the researchers identified three powerful predictors of rapid progression: being female, being naive to conventional synthetic disease-modifying drugs, and presenting with dactylitis. Specifically, having dactylitis at baseline increased the odds of progressing to polyarticular disease by more than nine-fold. These findings suggest a clear therapeutic window where early intervention can actively modify the disease course in high-risk patients.

In the same journal, a separate study investigated axial disease progression by analyzing a prospective psoriatic arthritis cohort followed from nineteen seventy-eight to twenty twenty-five [3]. Among more than fifteen hundred eligible patients followed for a median of six years, forty-five percent experienced radiographic progression of sacroiliitis by at least one grade. The investigators found that male sex, higher swollen joint counts, severe skin involvement, nail disease, syndesmophytes, elevated inflammatory markers, and higher disease activity scores were all associated with worsening sacroiliitis. Conversely, older age and exposure to biologic or targeted synthetic disease-modifying therapies were protective, with lower rates of progression observed in the modern treatment era. Taken together, these two studies emphasize that both peripheral and axial progression in psoriatic arthritis are highly driven by active inflammation, and that early, appropriate systemic therapy is crucial to preserving joint structure and preventing widespread joint involvement.

Next, we turn to the management of systemic autoimmune diseases, where new evidence challenges traditional cardiorenal treatment paradigms. In Lupus Science and Medicine, a retrospective study from the Treat-Systemic-Lupus-Erythematosus-to-Target registry evaluated whether adding renin-angiotensin system inhibitors is necessary during the intensive induction phase of active lupus nephritis [2]. While international guidelines routinely advocate for these agents to provide renoprotection, this practice has largely been extrapolated from non-lupus populations. The researchers compared over two hundred patients who received continuous renin-angiotensin system inhibitors during induction with ninety-four patients who did not. After applying propensity score weighting to balance baseline characteristics, the study revealed no significant difference in complete renal remission rates at twelve months or six months. Surprisingly, total renal remission at six months was significantly lower in the group receiving renin-angiotensin system inhibitors. Furthermore, these inhibitors did not accelerate proteinuria reduction or facilitate faster glucocorticoid tapering. The clinical takeaway here is highly practical: during active, severe lupus nephritis, the potent anti-inflammatory effect of induction immunosuppression appears to completely overshadow the hemodynamic, antiproteinuric effects of renin-angiotensin system inhibitors, suggesting we do not need to rush to initiate these agents during the acute induction phase.

In Rheumatology (Oxford), a multi-center quality improvement project across four major hospitals in the United Kingdom evaluated the real-world utility of advanced cardiovascular imaging in rare rheumatic diseases, including systemic lupus, systemic sclerosis, inflammatory myopathy, vasculitis, and primary Sjogren's disease [4]. Out of nearly three hundred imaging studies performed—which included cardiac magnetic resonance, computed tomography coronary angiography, and positron emission tomography—cardiovascular abnormalities were detected in nearly sixty percent of patients. Most notably, the vast majority of abnormal positron emission tomography scans and over two-thirds of abnormal cardiac magnetic resonance scans were identified in completely asymptomatic patients. These imaging findings were highly actionable, prompting treatment adjustments in nearly a third of patients and cardiology referrals in sixty percent. However, only twenty-three percent of these cases were discussed in a formal multidisciplinary team meeting. This highlights a critical need for establishing dedicated cardio-rheumatology multidisciplinary teams to coordinate care for these high-risk, asymptomatic patients.

We also saw important data regarding primary Sjogren's disease published in Rheumatology (Oxford), where researchers from the French ASSESS cohort evaluated the stability and prognostic value of B-cell biomarkers over five years [5]. While individual B-cell biomarkers remained highly stable in over eighty percent of the three hundred and sixty-two patients analyzed, the total baseline B-cell burden was highly prognostic. Patients who presented with five or more abnormal B-cell markers at baseline had a more than four-fold increased risk of experiencing persistent or worsening clinical disease activity over the five-year follow-up. This suggests that while serial testing of B-cell markers may not be necessary due to their longitudinal stability, a comprehensive baseline B-cell panel is a powerful tool to stratify patients and identify those who require closer monitoring and more aggressive management.

Our final theme focuses on novel clinical tools, phenotyping, and care delivery models that are reshaping how we manage chronic rheumatic conditions. In Seminars in Arthritis and Rheumatism, a clustering-based analysis of over five hundred patients with fibromyalgia identified three highly reproducible, clinically distinct phenotypes [6]. Cluster one represented a low-severity phenotype with preserved physical function; cluster two was characterized by prominent affective-sleep dysregulation with moderate pain; and cluster three reflected a high-severity, globally impaired phenotype. Crucially, these three distinct clusters emerged consistently in both medicated and unmedicated patient cohorts, demonstrating that these phenotypes are stable biological and clinical constructs rather than artifacts of treatment. This classification provides a solid foundation for designing future phenotype-guided, personalized therapeutic strategies.

For pediatric patients with juvenile idiopathic arthritis, a randomized controlled trial published in Rheumatology (Oxford) compared a traditional home-based exercise program to an immersive virtual reality exergaming program called JiaFitXR [7]. Both eight-week, physiotherapist-guided programs significantly improved physical fitness and daily activity in adolescents. However, the virtual reality group demonstrated significantly greater gains in lower extremity endurance, neuromuscular activation, and functional tests like the sit-to-stand and step tests, while the home-based group showed superior improvements in flexibility. This highlights immersive virtual reality as a highly engaging and effective tool to enhance lower extremity rehabilitation in younger populations.

We also saw the validation of the first disease-specific quality of life instrument for relapsing polychondritis, published in Rheumatology (Oxford) [8]. Developed by the European Reference Network ReCONNET, the thirty-one-item Relapsing Polychondritis Quality of Life instrument, or RP-QoL, was validated in over two hundred patients across nineteen countries. It demonstrated excellent internal consistency and correlated strongly with overall disease impact and standard physical and mental health scores, providing a much-needed, validated tool for both clinical trials and daily practice in this rare disease.

When it comes to visualizing structural hand pathology in systemic sclerosis, a systematic review in Seminars in Arthritis and Rheumatism evaluated twenty-five distinct imaging techniques, excluding ultrasound and nailfold capillaroscopy [9]. The review highlighted that magnetic resonance imaging is highly sensitive for detecting subclinical joint and soft-tissue inflammation, while computed tomography-based techniques offer superior quantification of calcinosis, and optical or photoacoustic methods show promise for skin fibrosis. However, the authors noted that a lack of standardization and longitudinal validation currently limits their widespread clinical implementation.

Finally, we must look at the broader landscape of rheumatology care delivery. The first edition of the EULAR RheumaFacts project, published in Annals of the Rheumatic Diseases, mapped health system indicators across thirty-six European countries, revealing stark inequalities [10]. The density of rheumatologists varied wildly, from less than one to over six per hundred thousand inhabitants. Furthermore, while conventional synthetic disease-modifying drugs are universally available, only about a third of countries have access to all biologic disease-modifying therapies, and only half have access to all targeted synthetic options. Reimbursement for essential non-pharmacological care was also highly restricted, with psychological support reimbursed in only thirty-nine percent of countries. These findings provide a vital baseline for national societies to advocate for systemic policy changes and more equitable patient care.

If you only have time for one paper this week, make it the FOREMOST trial on early psoriatic arthritis, published in Rheumatology (Oxford) [1]. This study provides the first robust clinical trial evidence that early intervention with apremilast during the oligoarticular phase can actively modify the disease course, reducing the odds of progression to debilitating polyarticular disease by fifty-eight percent. It also gives us clear, practical clinical red flags—namely female sex, conventional DMARD-naive status, and the presence of dactylitis—to identify which early psoriatic arthritis patients are at the highest risk of rapid deterioration and require immediate systemic therapy.

Here are the key takeaways from this week in Rheumatology.

In early, oligoarticular psoriatic arthritis, initiating apremilast significantly reduces the risk of progression to polyarticular disease, particularly in high-risk patients who are female, conventional DMARD-naive, or present with dactylitis.

During the intensive induction phase of active lupus nephritis, adding renin-angiotensin system inhibitors does not provide additive benefits for renal remission or steroid tapering, suggesting their hemodynamic effects are temporarily overshadowed by potent anti-inflammatory therapy.

Advanced cardiovascular imaging, including positron emission tomography and cardiac magnetic resonance, frequently identifies subclinical cardiovascular involvement in systemic autoimmune diseases, highlighting a critical role for future cardio-rheumatology multidisciplinary teams.

A high baseline B-cell biomarker burden in primary Sjogren's disease is a strong predictor of persistent or worsening disease activity over five years, offering a valuable tool for patient risk stratification despite the overall longitudinal stability of these markers.

Significant disparities exist across Europe in rheumatology workforce density, drug access, and non-pharmacological reimbursement, emphasizing the need for coordinated advocacy and health policy reform to ensure equitable patient care.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.